access and
support

Together, we got this

Let's talk coverage and support for your patients and about the resources available to help them along their treatment journey.

Key resources are only one click away.

For patients who are enrolled in Takeda Patient Support, our support specialists are available to help you and your patients understand what financial assistance options may be available.

See eligibility requirements below.

HelloHYQVIA
Free Trial Program

Help patients who are eligible find out if HyQvia is right for them with a free trial of HyQvia.

See eligibility requirements below.

Coverage
Lookup Tool

Use this lookup tool to determine specific plan coverage information for HyQvia in your area. Search for local coverage by entering a ZIP code.

Review safety information

Review Important Safety Information, including Contraindications and other specific Warnings and Precautions to consider when prescribing and monitoring patients treated with HyQvia.

See safety information

Help your patients access the treatment they need

Your patients may have questions regarding cost and coverage.

In this section, we have several educational resources to help you help your patients along the insurance journey.

Benefits investigation

Does my patient have coverage?
How much are their out-of-pocket costs?

Dual Benefit Brochure to help you understand the differences in coverage across Medical and Pharmacy Benefit.

Or you can access your patient’s coverage information for HyQvia in your area by using our Coverage Lookup Tool.

Dual Benefit Brochure

There are some health plans that cover HyQvia under the medical benefit, the pharmacy benefit, or both. Learn how this dual benefit design can impact how HyQvia is acquired and reimbursed.

Prior authorization

Prior authorizations (PAs) are commonly required in the approval process and each health plan has different requirements. Use these resources to help you submit the PA.

PA Checklist

Our PA checklist can help you meet the requirements and follow the procedures for requesting a PA to help ensure accurate and timely processing of PA requests.

Sample Letter of Medical Necessity (LMN)

An LMN supports the PA process by explaining the clinical rationale for HyQvia.

HyQvia Prescribing Information

Please click for Full Prescribing Information, including Black Box Warning.

Appeals process

If a PA gets denied, you can appeal the decision. The Appeals Checklist can help keep you on track. Some common reasons for denial are:

Missing or inaccurate information
Step-edit requirement
Incorrect diagnosis code(s) submitted
Billed to the wrong benefit (ie, medical vs pharmacy). To learn more, a basic overview and comparison of the
2 benefit designs is detailed here
Site of care for infusion is not preferred/not covered
Not covered on the formulary

Denials and Appeals Resource

Understand the appeals and denials process for both pharmacy and medical benefits.

Appeals Checklist

To assist with the PA and/or appeals process, use this checklist, which outlines documents to consider including.

Sample Letter of Appeal

Each appeal needs to clearly answer the reason for denial and the healthcare professional's clinical rationale. The sample letter can help get you started.

Reimbursement

HyQvia provides resources and information to help you process billing and diagnostic codes, as well as claim forms.

HyQvia Billing and Coding Guide

HyQvia is covered by many insurers for the treatment of patients. This guide contains common administrative and diagnostic codes related to HyQvia. The guide is provided for informational purposes and may not include all necessary codes.

CMS-1500 Claim Form

The CMS-1500 claim form is the standard claim form used to bill many government and private insurers. This sample is intended to assist you with completing the form for billing HyQvia and associated services.

Support when your patients need it

Takeda Patient Support will provide your patients with resources and guidance from dedicated support specialists who will address your patients’ questions and concerns and help them get the information they need, and nurse professionals who will provide education about their condition and their prescribed Takeda treatment. If English is not your patient’s preferred language, we can assist them in a language of their choosing.

Patients enrolled in Takeda Patient Support will have access to:

Financial assistance support

Insurance support

Medication delivery

Treatment and condition education

Takeda Patient Support Co-Pay Assistance Program*

If a patient is prescribed HyQvia and needs co-pay assistance, you can direct the patient to enroll in the Takeda Patient Support Co-Pay Assistance Program. The program can cover up to 100% of your patient’s out-of-pocket co-pay costs, if they’re eligible.^† A support specialist can review your patient's coverage and determine eligibility.

Eligibility

Be prescribed HyQvia
Have commercial insurance. This includes health insurance marketplace plans
Be enrolled in Takeda Patient Support

See below for terms and conditions.

If your patient has government insurance

Takeda Patient Support can help answer questions about their prescribed Takeda treatment coverage.

If your patient can’t afford treatment

Takeda Patient Support may be able to connect them to programs that may help.

Enroll patients today.
There are 3 ways to enroll.

Visit our convenient
online enrollment portal

Download and fax the
completed Start Form to
1-866-861-1752

Call Takeda Patient Support
at 1-866-861-1752,
Monday through Friday,
8 AM to 8 PM ET

*IMPORTANT NOTICE: The Takeda Patient Support Co-Pay Assistance Program (the Program) is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), Tricare, Medigap, VA, DoD, or other federal or state programs (including any medical or state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third-party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Copayment assistance under the Program is not transferable. The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your patient’s insurance provider. If your patient’s insurance situation changes, they must notify the Program immediately at 1-866-861-1750. Coverage of certain administration charges will not apply for patients residing in states where it is prohibited by law. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice.

^†If your patient's medication is dispensed by a specialty pharmacy.

Patient resources

HelloHYQVIA Free Trial Program

Help your eligible patients* determine
if HyQvia is right for them

With the HelloHYQVIA program, patients may be able to try HyQvia for free to help you and your patient determine if HyQvia is right for them.

Start the enrollment process for your patients today.

Download and complete the HelloHYQVIA Free Trial Program Request Form and fax to 1-833-388-5467
Healthcare professional (HCP) can check a box on the form if they want to have the pharmacist determine ramp-up dosing

Note: The pharmacist will call the HCP’s office to clarify ramp-up dosing if it is not written or the box is not checked.

The patient will receive a welcome call from a HelloHYQVIA Free Trial Program Case Manager.

The Case Manager will:

Ensure the patient has signed the HelloHYQVIA Free Trial Program Request Form
Connect the patient with the specialty pharmacy that will coordinate medication shipment
Connect the patient with a nurse who will help schedule administration training

The patient will receive their first 3 ramp-up HyQvia infusions either at home or in the office, depending on what is best. After completion of the program, communication will be sent to the HCP documenting the infusion rate and patient experience.

HelloHYQVIA Free Trial Program Request Form

Complete the form and fax to 1-833-388-5467

*Eligible patients must have an ICD-10 code verifying diagnosis, be a new patient not currently using HyQvia, and not have previously enrolled in the HelloHYQVIA program. Additional terms apply.

Patient education can play an important role in chronic disease management

Patient education is a vital component in caring for patients with chronic disease because it informs and involves patients in understanding both the disease state and the care instructions necessary for their condition. It also helps patients understand any lifestyle changes that they will need to make to help manage their condition. You can support your patients with the following resources.

Peristaltic infusion pump

How to infuse HyQvia with a peristaltic pump.

Patient experience videos

See how real HyQvia patients, Mary and Michael, infuse HyQvia.

Find comprehensive resources that provide support for your patients.

Explore comprehensive resources for your patients to help support them with their HyQvia treatment.

Why HyQvia brochure

Helps patients learn if HyQvia is right for them, while encouraging them to take the next step in their treatment journey.

DOWNLOAD NOW

Patient Starter Kit

The HyQvia Patient Starter Kit contains educational resources and materials to help facilitate their PI treatment.

To order starter kits, contact your specialty pharmacy.

Step-by-Step Infusion Guide

If your patient needs to learn how to infuse HyQvia using a peristaltic infusion pump, this step-by-step guide helps you walk them through all the necessary steps.

DOWNLOAD NOW

How to Infuse HyQvia with a Syringe Driver Pump

After you’ve ensured your patient is properly trained on how to administer their medication with a syringe driver pump, pass this guide along to help reinforce what they’ve learned.

DOWNLOAD NOW

Support from the start with resources throughout their journey

Find a strong support community and education resources for your patients with primary immunodeficiency, regardless of treatment.

MyIgSource is committed to helping your patients manage a life with primary immunodeficiency (PI) at diagnosis and throughout their PI journey. From advocacy to learning about diagnosis, management, and living with PI, your patients and their caregivers, regardless of treatment, have access to:

"We're in this together" MyIgSource's tagline.

Learn more about PI and managing their condition
Sign up to receive educational materials that can help them and their loved ones better understand PI
Connect by phone or online with patient advocates that have PI or have loved ones living with the condition
Register for events focusing on disease education related to PI

Have your patients connect at MyIgSource.com or call 1-855-250-5111.

Patient education can play an important role in chronic disease management

Patient education is a vital component in caring for patients with chronic disease because it informs and involves patients in understanding both the disease state and the care instructions necessary for their condition. It also helps patients understand any lifestyle changes that they will need to make to help manage their condition. You can support your patients with the following resources.

Infusion videos

Here’s a selection of infusion how-to videos.

Step-by-step infusion guide

See a nurse administering HyQvia at an infusion center.

Patient administration video

Watch a nurse help a patient learn how to self-infuse HyQvia at home.

Find comprehensive resources that may provide support for your patients.

Explore comprehensive resources for your patients to help support them with their HyQvia treatment.

Patient Starter Kit

The HyQvia Patient Starter Kit contains educational resources and materials to help facilitate their CIDP treatment.

Ask your representative about receiving a Patient Starter Kit.

Patient Experience & Symptom Tracker

Allows patients to track how their CIDP symptoms are doing over time.

Download Now

Considering HyQvia

Helps patients learn if HyQvia is right for them, while encouraging them to take the next step in their treatment journey.

Download Now

Doctor Discussion Guide

A useful tool that can help be a conversation starter about CIDP maintenance treatment goals.

Download Now

Have you checked out these organizations?

Their missions are to help your patients understand everything from diagnosis to clinical research and so much more.

The GBS | CIDP Foundation International is a global nonprofit organization supporting individuals and their families affected by Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and related conditions through a commitment to support, education, research, and advocacy.

Visit the site

The NAF is dedicated to ensuring neuropathy patients obtain the necessary resources, information, and tools to access individualized treatment to improve their quality of life.

Visit the site

The Foundation for Peripheral Neuropathy strives to cure painful neuropathies through collaborative research, education, and treatment.

Visit the site

Get answers to your questions. Talk to a representative about HyQvia.

Contact a Rep

Review Starting Patients

Home

Contact a Rep

IMPORTANT SAFETY INFORMATION including BOXED WARNING for Thrombosis

INDICATION

HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients two years of age and older. HYQVIA is for subcutaneous use only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin (IG) products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human IG
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG
Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA
Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)

Warnings and Precautions

Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis.

Thrombosis: Has been reported to occur following treatment with IG products, including HyQvia and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Immunogenicity of Recombinant Human Hyaluronidase (rHuPH20): Non-neutralizing antibodies to the Recombinant Human Hyaluronidase component can develop. The clinical significance of these antibodies or whether they interfere with fertilization in humans is unknown.

Aseptic Meningitis Syndrome: Has been reported with use of IG, including HyQvia and may occur more frequently in females. The syndrome usually begins within several hours to two days following IG treatment.
Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae.

Hemolysis: HYQVIA contains blood group antibodies which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing.

Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with intravenous (IV) use of IG products, especially those containing sucrose. Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and consider lower, more frequent dosing. If renal function deteriorates, consider discontinuation.

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Transfusion-Related Acute Lung Injury: Non-cardiogenic pulmonary edema may occur with IV administered IG. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.

Transmittable Infectious Agents: Because HYQVIA is made from human plasma, it may carry a risk of transmitting infectious agents (e.g. viruses, other pathogens). No cases of transmission of viral diseases or variant Creutzfeldt-Jakob disease (vCJD) have been associated with HYQVIA.

Interference with Lab Tests: False positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.

Adverse Reactions

The most common adverse reactions observed in >5% of patients in the clinical trials were: local adverse reactions including pain, erythema, edema, and pruritis, and systemic adverse reactions including, headache, antibody formation against Recombinant Human Hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use in Specific Populations

Pregnancy: Limited human data are available on the use of HyQvia during pregnancy. The effects of antibodies to the Recombinant Human Hyaluronidase on the human embryo or fetal development are unknown. It is not known whether HyQvia can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. HyQvia should be given to a pregnant woman only if clearly needed.

Please click for Full Prescribing Information.

INDICATION

HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients two years of age and older. HYQVIA is for subcutaneous use only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin (IG) products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human IG
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG
Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA
Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)

Warnings and Precautions

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Adverse Reactions

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use in Specific Populations

Please click for Full Prescribing Information.

IMPORTANT SAFETY INFORMATION including BOXED WARNING for Thrombosis

INDICATION

HYQVIA is indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults. HYQVIA is for subcutaneous use only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin (IG) products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human IG
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG
Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA
Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)

Warnings and Precautions

Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis.

Thrombosis: Has been reported to occur following treatment with IG products, including HYQVIA and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Immunogenicity of Recombinant Human Hyaluronidase (rHuPH20): Non-neutralizing antibodies to the Recombinant Human Hyaluronidase component can develop. The clinical significance of these antibodies or whether they interfere with fertilization in humans is unknown.

Aseptic Meningitis Syndrome: Has been reported with use of IG, including HYQVIA and may occur more frequently in females. The syndrome usually begins within several hours to two days following IG treatment.

Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae.

Hemolysis: HYQVIA contains blood group antibodies which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing.

Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with intravenous (IV) use of IG products, especially those containing sucrose. Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and consider lower, more frequent dosing. If renal function deteriorates, consider discontinuation.

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Transfusion-Related Acute Lung Injury: Non-cardiogenic pulmonary edema may occur with IV administered IG. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.

Transmittable Infectious Agents: Because HYQVIA is made from human plasma, it may carry a risk of transmitting infectious agents (e.g. viruses, other pathogens). No cases of transmission of viral diseases or variant Creutzfeldt-Jakob disease (vCJD) have been associated with HYQVIA.

Interference with Lab Tests: False positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.

Adverse Reactions

The most common adverse reactions observed in clinical trials in >5% of patients were: local reactions, headache, pyrexia, nausea, fatigue, erythema, pruritus, increased lipase, abdominal pain, back pain, and pain in extremity.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use In Specific Populations

Pregnancy: Limited human data are available on the use of HYQVIA during pregnancy. The effects of antibodies to the Recombinant Human Hyaluronidase on the human embryo or fetal development are unknown. It is not known whether HYQVIA can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. HYQVIA should be given to a pregnant woman only if clearly needed.

Please click for Full Prescribing Information.

INDICATION

HYQVIA is indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults. HYQVIA is for subcutaneous use only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin (IG) products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human IG
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG
Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA
Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)

Warnings and Precautions

Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis.

Thrombosis: Has been reported to occur following treatment with IG products, including HYQVIA and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Immunogenicity of Recombinant Human Hyaluronidase (rHuPH20): Non-neutralizing antibodies to the Recombinant Human Hyaluronidase component can develop. The clinical significance of these antibodies or whether they interfere with fertilization in humans is unknown.

Aseptic Meningitis Syndrome: Has been reported with use of IG, including HYQVIA and may occur more frequently in females. The syndrome usually begins within several hours to two days following IG treatment.

Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae.

Hemolysis: HYQVIA contains blood group antibodies which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing.

Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with intravenous (IV) use of IG products, especially those containing sucrose. Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and consider lower, more frequent dosing. If renal function deteriorates, consider discontinuation.

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Transfusion-Related Acute Lung Injury: Non-cardiogenic pulmonary edema may occur with IV administered IG. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.

Transmittable Infectious Agents: Because HYQVIA is made from human plasma, it may carry a risk of transmitting infectious agents (e.g. viruses, other pathogens). No cases of transmission of viral diseases or variant Creutzfeldt-Jakob disease (vCJD) have been associated with HYQVIA.

Interference with Lab Tests: False positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.

Adverse Reactions

The most common adverse reactions observed in clinical trials in >5% of patients were: local reactions, headache, pyrexia, nausea, fatigue, erythema, pruritus, increased lipase, abdominal pain, back pain, and pain in extremity.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use In Specific Populations

Pregnancy: Limited human data are available on the use of HYQVIA during pregnancy. The effects of antibodies to the Recombinant Human Hyaluronidase on the human embryo or fetal development are unknown. It is not known whether HYQVIA can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. HYQVIA should be given to a pregnant woman only if clearly needed.

Please click for Full Prescribing Information.

©2024 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA^®, the TAKEDA Logo^®, and the TAKEDA Patient Support Logo^® are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. HYQVIA^® and MYIGSOURCE™ are trademarks or registered trademarks of Baxalta Incorporated.
US-HYQ-1214v1.0 05/24

About Takeda
Privacy Notice
Terms & Conditions
Site Map
To Patient Site
Contact Us
Manage Communications Preferences
Sign Up for Updates

©2024 Takeda Pharmaceuticals U.S.A., Inc., 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA^®, the TAKEDA Logo^®, and the TAKEDA Patient Support Logo^® are registered trademarks of Takeda Pharmaceutical Company Limited. HYQVIA^® is a registered trademark of Baxalta Incorporated.
US-HYQ-0587v1.0 04/24

Thank you for visiting

You are now leaving this site and being redirected to a non-Takeda owned/managed website.

Continue

Never mind, I want to stay

Hy, healthcare professionals

The information on this website is technical in nature and has been specifically created for healthcare professionals. If you are not a healthcare professional and would like to visit the patient site, please visit www.HyQvia.com

Continue

Take me to the patient site

Thank you for visiting

You are being directed to another website.

Continue

Never mind, I want to stay

Say Hy to access and support

Together, we got this

Review safety information

Review safety information

Step 1: Download and complete the HyQvia Start Form

Step 2: Your patient will receive a welcome call from their Case Manager

Step 3: Begin HyQvia infusions

Patient education can play an important role in chronic disease management

Peristaltic infusion pump

Patient experience videos

Find comprehensive resources that provide support for your patients.

Why HyQvia brochure

Patient Starter Kit

Step-by-Step Infusion Guide

How to Infuse HyQvia with a Syringe Driver Pump

Support from the start with resources throughout their journey

Thank you for visiting

Thank you for visiting

Healthcare professionals

Thank you for visiting

Hy, healthcare professionals

Thank you for visiting